Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Powles, Thomas; P. Valderrama, Begoña; Gupta, Shilpa; Bedke, Jens; Kikuchi, Eiji; Hoffman‐Censits, Jean; Iyer, Gopa; Vulsteke, Christof; Hoon Park, Se; Joon Shin, Sang; Castellano, Daniel; Fornarini, Giuseppe; Li, Jian‐Ri; Gümüş, Mahmut; Mar, Nataliya; Loriot, Yohann; Fléchon, Aude; Durán, Ignacio; Drakaki, Alexandra; Narayanan, Sujata; Yu, Xuesong; Rao Gorla, Seema; Homet Moreno, Blanca; S. van der Heijden, Michiel

doi:10.1056/nejmoa2312117

Public

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Published in New England Journal of Medicine • Mar 6, 2024

Authors:

Thomas Powles

Begoña P. Valderrama

Shilpa Gupta

Abstract

BACKGROUND: No treatment has surpassed platinum-based chemotherapy in improving overall survival in patients with previously untreated locally advanced or metastatic urothelial carcinoma. METHODS: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfo...

Subject

Pembrolizumab

Medicine

Carboplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!